Genetics

Biogen’s Lead Alzheimer’s Drug Falls Down at Phase Three Trials

Pharma giant Biogen and its Japanese partner Eisai have made the decision to halt two phase 3 trials of aducanumab, a drug created to slow Alzheimer’s by targeting brain-destroying beta-amyloid fragments. An independent monitoring committee decided that the drug was unlikely to benefit patients compared with a placebo.

Gene Insertion Allows Blind Mice to See Again

Scientists from the University of California have announced a possible alternative option to electronic eye implants for those who have lost their sight: gene therapy. Virus-delivered genes for green opsin gave blind mice sight enough to determine patterns on an iPad, they found, with the therapy possibly ready for clinical trials in three years’ time.

Researchers Identify PTSD Blood Biomarkers

Indiana University School of Medicine researchers have found blood-based genetic markets of psychological stress which could lead to better diagnostics for post-traumatic stress disorder (PTSD), and bring forward new drug development leads.

Second Set of “Semi-Identical Twins” Identified

Twins born in Australia have become the second-ever-identified pair of “semi-identical” twins, and the first to be detected before they were born. Such cases come about when twins receive 100% identical genes from their mother, but not from their father.

How to Recruit a High-Performing Apprentice: Anglia Ruskin Panel Event

In September 2019, Anglia Ruskin University’s (ARU’s) Cambridge campus will begin the first year of its new – and currently unique in the UK – Data Scientist Degree Apprenticeship for the bioinformatics profession. Ahead of this, ARU and the Wellcome Sanger Institute have set up a “Lunch and Learn” panel event for hiring managers and talent acquisition specialists, looking at how they can best recruit and support top apprentices.